{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:05:14Z","timestamp":1781690714060,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The occurrence of multiple primary prostate malignant tumors is extremely rare and there is no consensus on its diagnosis and treatment. This article presents an elderly male patient with both acinar adenocarcinoma of the prostate and small lymphocytic lymphoma (SLL) invading the prostate. He was treated with ibrutinib for the lymphoma and goserelin and bicalutamide for the prostate cancer, resulting in control of both conditions. This case highlights the complexity of diagnosing and managing multiple synchronous prostate malignancies. TP53 mutation may play a central role in dual clonal evolution. Multidisciplinary collaboration and individualized treatment plans are essential in managing rare presentations of prostate MPMT.<\/jats:p>","DOI":"10.3389\/fonc.2025.1583504","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:20:34Z","timestamp":1749705634000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of multiple primary prostate malignant tumors: case report of synchronous prostatic adenocarcinoma and lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Weihuang","family":"Zhuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","article-title":"Multiple primary tumours: challenges and approaches, a review","volume":"2","author":"Vogt","year":"2017","journal-title":"ESMO Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.25482","article-title":"Multiple primary Malignant tumors - A clinical analysis of 15,321 patients with Malignancies at a single center in China","volume":"9","author":"Zhai","year":"2018","journal-title":"J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.12.035","article-title":"Multiple primary Malignancies","volume":"31","author":"Luciani","year":"2004","journal-title":"Semin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global burden of prostate cancer and association with socioeconomic status, 1990-2019: A systematic analysis from the global burden of disease study","volume":"13","author":"Zhang","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64242-3","article-title":"Hematolymphoid Malignancies diagnosed at the time of radical prostatectomy","volume":"158","author":"Terris","year":"1997","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other Malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2000.00855.x","article-title":"Adenocarcinoma and non-Hodgkin\u2019s lymphoma involving the prostate","volume":"36","author":"L\u00f3pez","year":"2000","journal-title":"Histopathology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","article-title":"Biological and therapeutic impact of intratumor heterogeneity in cancer evolution","volume":"27","author":"McGranahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.3390\/ijms17122142","article-title":"Tumour heterogeneity: the key advantages of single-cell analysis","volume":"17","author":"Tellez-Gabriel","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","article-title":"Intra-tumor heterogeneity from a cancer stem cell perspective","volume":"16","author":"Prasetyanti","year":"2017","journal-title":"Mol Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2017.03.001","article-title":"A population genetics perspective on the determinants of intra-tumor heterogeneity","volume":"1867","author":"Hu","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.15386\/mpr-2639","article-title":"TP53 gene implications in prostate cancer evolution: potential role in tumor classification","volume":"96","author":"Schitcu","year":"2023","journal-title":"Med Pharm Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2023.14.3.7","article-title":"Managing the patient with multiple primary tumors","volume":"14","author":"Chitwood","year":"2023","journal-title":"J Adv Pract Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.06.001","article-title":"EAU guidelines on prostate cancer","volume":"48","author":"Aus","year":"2005","journal-title":"Eur Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583504\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:20:34Z","timestamp":1749705634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1583504\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":22,"alternative-id":["10.3389\/fonc.2025.1583504"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1583504","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1583504"}}